lenalidomide has been researched along with vadimezan in 1 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 272 | 16 | 101 |
| Protein | Taxonomy | lenalidomide (IC50) | vadimezan (IC50) |
|---|---|---|---|
| Stimulator of interferon genes protein | Mus musculus (house mouse) | 1.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ching, LM; Connor, B; Guise, C; McGregor, A; Seyfoddin, V; Tijono, S; Yung, R | 1 |
1 other study(ies) available for lenalidomide and vadimezan
| Article | Year |
|---|---|
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Female; Glioma; Infusions, Subcutaneous; Lenalidomide; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Random Allocation; Thalidomide; Xanthones | 2014 |